TAP 311

Drug Profile

TAP 311

Alternative Names: TAP311

Latest Information Update: 11 Mar 2016

Price : $50

At a glance

  • Originator Novartis
  • Class Antihyperlipidaemics
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • No development reported Dyslipidaemias

Most Recent Events

  • 12 Dec 2012 Novartis completes a phase I trial in Dyslipidaemias in USA, Taiwan & Jordan (NCT01632358)
  • 30 Jun 2012 Phase-I clinical trials in Dyslipidaemias in Jordan (PO)
  • 30 Jun 2012 Phase-I clinical trials in Dyslipidaemias in Taiwan (PO)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top